[PCSK9 inhibitors: new treatment to lower cholesterol].

Gencer, Baris; Rodondi, Nicolas; Mach, François (2016). [PCSK9 inhibitors: new treatment to lower cholesterol]. Revue médicale suisse, 12(508), pp. 440-442. Médecine & Hygiène

[img] Text
Gencer RevMedSuisse 2016.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors appear to represent an important development in the management of hypercholesterolemia. US Food and Drug Administration and European Medicines Agency approved alirocumab and evolocumab, injected drugs administered subcutaneously every 2 or 4 weeks, for patients with hypercholesterolemia, such as those who not reached the cholesterol targets or those with intolerance to statin, especially in secondary prevention or familial hypercholesterolemia. This decision is based on several clinical trials suggesting that these drugs have a powerful effect on levels of LDL-cholesterol with an acceptable safety compared to placebo. Large clinical studies are currently performed to assess the impact of PCSK9 inhibitors on major adverse cardiovascular events in secondary prevention.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine > Centre of Competence for General Internal Medicine

UniBE Contributor:

Rodondi, Nicolas

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0025-6749

Publisher:

Médecine & Hygiène

Language:

French

Submitter:

Doris Kopp Heim

Date Deposited:

10 Jan 2017 11:20

Last Modified:

13 Jan 2017 11:09

PubMed ID:

27089600

BORIS DOI:

10.7892/boris.92363

URI:

https://boris.unibe.ch/id/eprint/92363

Actions (login required)

Edit item Edit item
Provide Feedback